S-Talazoparib, with the CAS number 1207456-00-5, is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair processes. This compound is primarily utilized in cancer therapy, particularly for treating certain types of breast and ovarian cancers associated with BRCA1 and BRCA2 mutations. S-Talazoparib exhibits a high affinity for the PARP enzyme, leading to the accumulation of DNA damage in cancer cells, ultimately inducing cell death. The substance is characterized by its small molecular weight and specific structural features that enhance its binding to the PARP active site. It is typically administered orally and has been studied for its efficacy in combination with other therapeutic agents. As a member of the class of PARP inhibitors, S-Talazoparib represents a significant advancement in targeted cancer treatment, offering a mechanism that exploits the deficiencies in DNA repair pathways present in certain tumors. Its development reflects ongoing research into personalized medicine approaches in oncology.

S-Talazoparib

1207456-00-5: S-Talazoparib, with the CAS number 1207456-00-5, is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair processes. This compound is primarily utilized in cancer therapy, particularly for treating certain types of breast and ovarian cancers associated with BRCA1 and BRCA2 mutations. S-Talazoparib exhibits a high affinity for the PARP enzyme, leading to the accumulation of DNA damage in cancer cells, ultimately inducing cell death. The substance is characterized by its small molecular weight and specific structural features that enhance its binding to the PARP active site. It is typically administered orally and has been studied for its efficacy in combination with other therapeutic agents. As a member of the class of PARP inhibitors, S-Talazoparib represents a significant advancement in targeted cancer treatment, offering a mechanism that exploits the deficiencies in DNA repair pathways present in certain tumors. Its development reflects ongoing research into personalized medicine approaches in oncology.

BMN 673 (8R,9S)

<p>(8R,9S)-Talazoparib is Talazoparib enantiomer , less active than Talazoparib on the inhibition of PARP1 (IC50: 144 nM).</p>

CAS 1207456-00-5

S-Talazoparib

BMN 673 (8R,9S)

Ref: IN-DA008TEK

(8R,9S)-Talazoparib

Ref: TM-T10564